AUTL — Autolus Therapeutics plc
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1730463 ·
Last close
$1.68
Market Cap
$447.12M
52W High
$1.95
52W Low
$1.17
ADV30
1,531,329
Next earnings
2026-08-14
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 26,218,000 | 1,650,000 | -59,513,000 | -71,598,000 | 527,065,000 | 130,925,000 | 418,239,000 |
| Dec 2025 | 24,289,000 | -1,041,000 | -72,469,000 | -90,332,000 | 589,068,000 | 104,132,000 | 410,939,000 |
| Sep 2025 | 21,194,000 | -7,449,000 | -71,621,000 | -79,118,000 | 661,947,000 | 86,124,000 | 396,495,000 |
| Jun 2025 | 20,923,000 | -3,522,000 | -61,217,000 | -47,917,000 | 720,981,000 | 123,825,000 | 374,517,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-283,568,000
Investing CF
$158,458,000
Financing CF
$-4,339,000
CapEx
$-51,873,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.05
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,386,752,000
Inventory
$33,209,000
Receivables
$75,789,000
ST Investments
$196,578,000
EBIT TTM
$-255,755,000
Pretax Income TTM
$-285,557,000
Interest Exp TTM
$12,664,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,078,500
EBITDA
$-68,942,608
Free Cash Flow
—
Enterprise Value
$-151,314,048
Total Cash
$217,450,000
Total Debt
$0
Shares Out
266,143,286
Trailing EPS
$-1.09
Book Value
$5.91
ROE
-29.6%
ROA
-22.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 75,388,000 | -270,544,000 | -287,528,000 | 589,068,000 | 410,939,000 | — | -283,568,000 |
| Dec 2024 | 10,120,000 | -241,426,000 | -220,662,000 | 782,725,000 | 355,400,000 | — | -206,271,000 |
| Dec 2023 | 1,698,000 | -175,528,000 | -208,383,000 | 375,381,000 | 263,907,000 | — | -145,587,000 |
| Dec 2022 | 6,194,000 | -142,893,000 | -148,839,000 | 490,274,000 | 191,600,000 | — | -112,308,000 |
TTM Snapshot
Revenues TTM
$3,811,000
NetIncome TTM
$-170,710,000
OpCashFlow TTM
$0
Assets (Latest)
$782,725,000
Forward EPS
$-0.62
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OCGN | Ocugen, Inc. | $453.62M | $1.34 | — |
| STRO | SUTRO BIOPHARMA, INC. | $453.70M | $27.38 | — |
| FDMT | 4D Molecular Therapeutics, Inc. | $455.33M | $8.71 | — |
| DNA | Ginkgo Bioworks Holdings, Inc. | $463.71M | $8.69 | — |
| LXEO | Lexeo Therapeutics, Inc. | $403.60M | $5.14 | — |
News headlines (Yahoo Finance, 1h cache)
European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading
2026-05-22 15:06 · Yahoo
Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026
2026-05-21 21:10 · Yahoo
European Equities Traded in the US as American Depositary Receipts Little Changed in Thursday Trading
2026-05-21 15:05 · Yahoo
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading
2026-05-19 15:27 · Yahoo
European Equities Traded in the US as American Depositary Receipts Open Week Tracking Higher in Monday Trading
2026-05-18 15:11 · Yahoo
Autolus Therapeutics PLC (AUTL) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...
2026-05-14 23:02 · Yahoo
European Equities Traded in the US as American Depositary Receipts Tracking Higher in Thursday Trading
2026-05-14 15:05 · Yahoo
Autolus Therapeutics Q1 Earnings Call Highlights
2026-05-14 14:07 · Yahoo
Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
2026-05-14 11:00 · Yahoo
European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading
2026-05-13 15:12 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.